Ticker > Company >

Lyka Labs share price

Lyka Labs Ltd.

NSE: LYKALABS BSE: 500259 SECTOR: Pharmaceuticals & Drugs  42.27 K   76   5

99.40
+0.18 (0.18%)
BSE: 05 Sep 04:01 PM

Price Summary

Today's High

₹ 100.58

Today's Low

₹ 97.71

52 Week High

₹ 175.95

52 Week Low

₹ 90.2

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

354.76 Cr.

Enterprise Value

391.44 Cr.

No. of Shares

3.57 Cr.

P/E

48.64

P/B

2.61

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  38.04

CASH

1.32 Cr.

DEBT

38 Cr.

Promoter Holding

58.16 %

EPS (TTM)

₹  2.04

Sales Growth

26.6%

ROE

7.31 %

ROCE

8.38%

Profit Growth

462.59 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year26.6%
3 Year-6.42%
5 Year27.02%

Profit Growth

1 Year462.59%
3 Year-40.92%
5 Year16.53%

ROE%

1 Year7.31%
3 Year-7.14%
5 Year3.45%

ROCE %

1 Year8.38%
3 Year3.3%
5 Year12.32%

Debt/Equity

0.2816

Price to Cash Flow

108.42

Interest Cover Ratio

5.9793

CFO/PAT (5 Yr. Avg.)

5.27303339773668

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 58.16 0.00
Mar 2025 58.16 0.00
Dec 2024 58.10 0.00
Sep 2024 58.10 0.00
Jun 2024 58.10 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 18.7041 Cr.
  • The Company has been maintaining an effective average operating margins of 25.763274930163% in the last 5 years.
  • Company’s PEG ratio is 0.111523924499678.
  • The company has an efficient Cash Conversion Cycle of 34.6815 days.
  • The company has a good cash flow management; CFO/PAT stands at 5.27303339773668.
  • The company has a high promoter holding of 58.16%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 7.37876733855405.

 Limitations

  • The company has shown a poor profit growth of -40.9230532401072% for the Past 3 years.
  • The company has shown a poor revenue growth of -6.41680968686604% for the Past 3 years.
  • Company has a poor ROE of -7.1422% over the past 3 years.
  • Company has a poor ROCE of 3.30006666666667% over the past 3 years
  • The company is trading at a high PE of 48.64.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 30.11 41.16 32.92 30.52 29.18
Total Expenditure 26.05 35.82 27.84 27.11 25.79
Operating Profit 4.06 5.34 5.09 3.41 3.39
Other Income 0.62 0.13 0.87 0.72 0.67
Interest 0.65 0.52 0.62 0.52 0.85
Depreciation 1.68 1.68 1.75 1.34 2.03
Exceptional Items 0 0 0 0 0
Profit Before Tax 2.35 3.27 3.59 2.27 1.17
Tax 0.6 0.8 0.89 0.97 0.36
Profit After Tax 1.75 2.47 2.7 1.31 0.81
Adjusted EPS (Rs) 0.49 0.69 0.76 0.37 0.23

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 62.26 164.35 80.59 106.4 134.7
Total Expenditure 47.84 66.85 64.99 91.84 116.81
Operating Profit 14.43 97.5 15.6 14.56 17.89
Other Income 2.21 2.72 3.45 1.65 2.34
Interest 25.55 19.92 11.57 4.8 2.3
Depreciation 8.05 15.39 13.52 12.29 6.45
Exceptional Items -1.43 -4.67 -7.17 -0.06 0
Profit Before Tax -18.4 60.24 -13.21 -0.93 11.47
Tax -3.94 20.34 0.08 1.34 3.25
Net Profit -14.46 39.9 -13.29 -2.27 8.23
Adjusted EPS (Rs.) -5.04 13.91 -4.33 -0.69 2.31

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 28.69 28.69 30.69 33.09 35.69
Total Reserves -24.28 15.75 45.74 66.24 99.25
Borrowings 151.06 61.63 63.4 42.91 19.21
Other N/C liabilities -3.71 8.77 9.06 7.87 6.65
Current liabilities 45.39 93.68 29.97 35.91 44.78
Total Liabilities 197.15 208.51 178.86 186.02 205.58
Assets
Net Block 95.34 90.11 65.53 55.64 84.44
Capital WIP 16.18 16.23 15.1 21.97 0.2
Intangible WIP 8.22 1.51 1.12 1.08 1
Investments 32.4 32.4 32.4 32.4 32.4
Loans & Advances 19.28 21.06 22.41 25.05 21.42
Other N/C Assets 0 0 0 0 0
Current Assets 25.74 47.19 42.3 49.86 66.12
Total Assets 197.15 208.51 178.86 186.02 205.58
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations -18.4 60.24 -13.21 -0.93 11.47
Adjustment 33.97 37.6 31.31 16.66 8.44
Changes in Assets & Liabilities -9.1 -20.76 -10.81 -11.16 -13.66
Tax Paid -0.72 -0.55 -0.41 -1.47 -2.98
Operating Cash Flow 5.75 76.53 6.87 3.09 3.27
Investing Cash Flow 0.13 -4.33 6.77 -8.61 -13.1
Financing Cash Flow -7.75 -63.35 -20.33 2.71 5.26
Net Cash Flow -1.88 8.85 -6.69 -2.81 -4.57

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 58.10 58.10 58.10 58.16 58.16
alisha kunal gandhi - - - 0.13 0.13
bhawna godha 0.02 0.02 0.02 0.02 0.02
enai trading and investme... 2.80 2.80 2.80 2.80 2.80
ipca laboratories limited... 40.98 40.98 40.98 40.98 40.98
kunal narendra gandhi 6.79 6.79 6.79 9.79 9.79
lyka generics limited 0.06 0.06 0.06 0.06 0.06
neetu godha 0.03 0.03 0.03 0.03 0.03
nehal narendra gandhi 6.53 6.53 6.53 3.46 3.26
pranay godha 0.84 0.84 0.84 0.84 0.84
premchand godha 0.03 0.03 0.03 0.03 0.03
sweta shah - - - - 0.11
usha godha - - - - 0.03
ushma ronak shah - - - - 0.09
usha premchand godha 0.03 0.03 0.03 0.03 -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 41.90 41.90 41.90 41.84 41.84
dalal & broacha stock bro... - - - 1.12 1.12
llp 0.62 0.63 0.64 0.85 0.87
thermo capital private li... - - - 1.55 1.53
thermo pads private limit... 2.29 1.76 1.41 - -

Annual Reports

Title Link
Title Link
Annual Report 2025
Annual Report 2023
Annual Report 2023
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit INDIA RATINGS
Credit FITCH
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Lyka Labs informs about GST Audit 5 Sep, 5:51 PM Lyka Labs - Quaterly Results 1 Aug, 12:50 PM Lyka Labs - Quaterly Results 1 Aug, 12:50 PM Lyka Labs - Quaterly Results 1 Aug, 12:50 PM Lyka Labs informs about board meeting 21 Jul, 2:54 PM Lyka Labs - Quaterly Results 26 May, 6:44 PM Lyka Labs - Quaterly Results 26 May, 6:44 PM Lyka Labs gets Indian patent for Pregabalin Gel 8% 8 Apr, 2:42 PM Lyka Labs informs about press release 8 Apr, 2:17 PM Lyka Labs informs about certificate 4 Apr, 4:52 PM Lyka Lab informs about voting results and scrutinizer’s report 5 Mar, 5:13 PM Lyka Labs informs about integrated filing 5 Feb, 3:53 PM Lyka Labs informs about outcome of board meeting 4 Feb, 5:09 PM Lyka Labs - Quaterly Results 4 Feb, 3:11 PM Lyka Labs - Quaterly Results 4 Feb, 3:11 PM Lyka Labs - Quaterly Results 4 Feb, 3:11 PM Lyka Labs informs about scheme of amalgamation 24 Jan, 3:02 PM Lyka Labs informs about board meeting 30 Dec, 5:16 PM Lyka Labs - Quaterly Results 12 Nov, 12:55 PM Lyka Labs - Quaterly Results 12 Nov, 12:55 PM Lyka Labs informs about scheme of amalgamation 26 Oct, 12:54 PM Lyka Labs informs about board meeting 4 Oct, 12:40 PM Lyka Labs informs about newspaper advertisement 12 Aug, 12:26 PM Lyka Labs - Quaterly Results 9 Aug, 1:31 PM Lyka Labs - Quaterly Results 9 Aug, 1:31 PM Lyka Labs - Quaterly Results 9 Aug, 1:31 PM Lyka Labs informs about newspaper publication of AGM 18 Jul, 2:40 PM Lyka Labs informs about press release 16 Jul, 5:30 PM Lyka Labs informs about details of loss of certificate 26 Jun, 2:12 PM Lyka Labs - Quaterly Results 21 May, 5:47 PM Lyka Labs - Quaterly Results 21 May, 5:47 PM Lyka Labs informs about change in time of board meeting 14 May, 10:39 AM Lyka Labs informs about board meeting 10 May, 2:47 PM Lyka Labs informs about disclosure 18 Apr, 3:35 PM Lyka Labs - Quaterly Results 8 Feb, 1:44 PM Lyka Labs - Quaterly Results 8 Feb, 1:44 PM Lyka Labs - Quaterly Results 8 Feb, 1:44 PM Lyka Labs informs about change in directorate 16 Jan, 3:12 PM Lyka Labs informs about loss of share certificates 3 Jan, 2:21 PM Lyka Labs informs about issuance of duplicate share certificates 1 Dec, 3:21 PM Lyka Labs informs about update on scheme of amalgamation 25 Nov, 3:20 PM Lyka Labs - Quaterly Results 2 Nov, 1:56 PM Lyka Labs - Quaterly Results 2 Nov, 1:56 PM Lyka Labs - Quaterly Results 2 Nov, 1:56 PM Lyka Labs informs about disclosure 10 Oct, 4:20 PM Lyka Labs gets product permission from CDSCO for Tofacitinib Ointment 10 Oct, 12:11 PM Lyka Labs informs about change in directorate 27 Sep, 4:41 PM Lyka Lab informs about issuance of duplicate share certificate 26 Sep, 2:25 PM Lyka Labs informs about details of loss of certificate 24 Aug, 5:05 PM Lyka Labs informs about loss of share certificates 21 Aug, 5:18 PM

Lyka Labs Stock Price Analysis and Quick Research Report. Is Lyka Labs an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Lyka Labs. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Lyka Labs has a PE ratio of 48.6639913869042 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Lyka Labs has ROA of 4.2019% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Lyka Labs has a Current ratio of 1.4764.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Lyka Labs has a ROE of 7.3065%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Lyka Labs has a Debt to Equity ratio of 0.2816 which means that the company has low proportion of debt in its capital.

  • Sales growth: Lyka Labs has reported revenue growth of 26.5997% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Lyka Labs for the current financial year is 13.2807314766283%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Lyka Labs is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Lyka Labs is Rs 2.0434. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Lyka Labs in Ticker for free. Also, one can get the intrinsic value of Lyka Labs by using Valuation Calculators, which are available with a Finology ONE subscription. 

Lyka Labs FAQs

Q1. What is Lyka Labs share price today?
Ans: The current share price of Lyka Labs is Rs 99.44.

Q2. What is the market capitalisation of Lyka Labs?
Ans: Lyka Labs has a market capitalisation of Rs 354.90136 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Lyka Labs?
Ans: The PE ratio of Lyka Labs is 48.6639913869042 and the P/B ratio of Lyka Labs is 2.61429660593632, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Lyka Labs share?
Ans: The 52-week high share price of Lyka Labs is Rs 176.59, and the 52-week low share price of Lyka Labs is Rs 96.8.

Q5. Does Lyka Labs pay dividends?
Ans: Currently, Lyka Labs does not pay dividends. Dividend yield of Lyka Labs is around 0%.

Q6. What are the face value and book value of Lyka Labs shares?
Ans: The face value of Lyka Labs shares is Rs 10, while the book value per share of Lyka Labs is around Rs 38.037. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Lyka Labs?
Ans: Lyka Labs has a total debt of Rs 37.9954 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Lyka Labs?
Ans: The ROE of Lyka Labs is 7.3065% and ROCE of Lyka Labs is 8.3773%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Lyka Labs a good buy for the long term?
Ans: The Lyka Labs long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Lyka Labs undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Lyka Labs appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Lyka Labs’s financials?
Ans: You can review Lyka Labs’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Lyka Labs
X